Divi's Laboratories Ltd (DIVISLAB) - Financial and Strategic SWOT Analysis Review
Description
Divi's Laboratories Ltd (DIVISLAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Divi's Laboratories Ltd (Divi) is a pharmaceutical company. It manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates. The company’s product portfolio consists of generic APIs, custom synthesis, and nutraceuticals. The company offers products that include bupropion HCl, diltiazem HCl, carbidopa, dextromethorphan HBr, gabapentin, irbesartan, lacosamide, naproxen sodium, quetiapine fumarate, triprolidine HCl, valacyclovir HCl, venlafaxine HCl, valsartan, and nutraceuticals including beta carotene, astaxanthin, lycopene, and canthaxanthin. Its extensive API portfolio consists of medications for various disease conditions, including cardiovascular, inflammation, cancer, and central nervous system treatments. It offers contract manufacturing services for APIs and intermediates of various compounds. It operates manufacturing plants in Hyderabad and Visakhapatnam, India. The company’s Generic APIs division has operations in over 100 countries. Divi is headquartered in Hyderabad, Telangana, India.
Divi's Laboratories Ltd Key Recent Developments
Nov 07,2025: Divi’s Laboratories Earns a Consolidated Total Income of 2860 Crores for Q2 of FY26
Aug 06,2025: Divi's Labs Earns a Consolidated Total Income of 2529 Crores for Q1 of FY2025-26
Feb 03,2025: Divi's Laboratories : Intimation of changes in Senior Management Personnel
Jul 19,2024: US-FDA Inspection of Company’s Unit-II Manufacturing Facility at Visakhapatnam, Andhra Pradesh
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Divi's Laboratories Ltd (Divi) is a pharmaceutical company. It manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates. The company’s product portfolio consists of generic APIs, custom synthesis, and nutraceuticals. The company offers products that include bupropion HCl, diltiazem HCl, carbidopa, dextromethorphan HBr, gabapentin, irbesartan, lacosamide, naproxen sodium, quetiapine fumarate, triprolidine HCl, valacyclovir HCl, venlafaxine HCl, valsartan, and nutraceuticals including beta carotene, astaxanthin, lycopene, and canthaxanthin. Its extensive API portfolio consists of medications for various disease conditions, including cardiovascular, inflammation, cancer, and central nervous system treatments. It offers contract manufacturing services for APIs and intermediates of various compounds. It operates manufacturing plants in Hyderabad and Visakhapatnam, India. The company’s Generic APIs division has operations in over 100 countries. Divi is headquartered in Hyderabad, Telangana, India.
Divi's Laboratories Ltd Key Recent Developments
Nov 07,2025: Divi’s Laboratories Earns a Consolidated Total Income of 2860 Crores for Q2 of FY26
Aug 06,2025: Divi's Labs Earns a Consolidated Total Income of 2529 Crores for Q1 of FY2025-26
Feb 03,2025: Divi's Laboratories : Intimation of changes in Senior Management Personnel
Jul 19,2024: US-FDA Inspection of Company’s Unit-II Manufacturing Facility at Visakhapatnam, Andhra Pradesh
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
46 Pages
- Section 1 - About the Company
- Divi's Laboratories Ltd - Key Facts
- Divi's Laboratories Ltd - Key Employees
- Divi's Laboratories Ltd - Key Employee Biographies
- Divi's Laboratories Ltd - Major Products and Services
- Divi's Laboratories Ltd - History
- Divi's Laboratories Ltd - Company Statement
- Divi's Laboratories Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- Divi's Laboratories Ltd - Business Description
- Geographical Segment: America
- Performance
- Geographical Segment: Asia
- Performance
- Geographical Segment: Europe
- Performance
- Geographical Segment: India
- Performance
- Geographical Segment: Rest of the world
- Performance
- R&D Overview
- Divi's Laboratories Ltd - Corporate Strategy
- Divi's Laboratories Ltd - SWOT Analysis
- SWOT Analysis - Overview
- Divi's Laboratories Ltd - Strengths
- Divi's Laboratories Ltd - Weaknesses
- Divi's Laboratories Ltd - Opportunities
- Divi's Laboratories Ltd - Threats
- Divi's Laboratories Ltd - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- Divi's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Divi's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Divi's Laboratories Ltd, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Nov 07, 2025: Divi’s Laboratories Earns a Consolidated Total Income of 2860 Crores for Q2 of FY26
- Aug 06, 2025: Divi's Labs Earns a Consolidated Total Income of 2529 Crores for Q1 of FY2025-26
- Feb 03, 2025: Divi's Laboratories : Intimation of changes in Senior Management Personnel
- Jul 19, 2024: US-FDA Inspection of Company’s Unit-II Manufacturing Facility at Visakhapatnam, Andhra Pradesh
- Jun 22, 2024: Divi's Laboratories : Completion of Tenure of an Independent Director
- Apr 25, 2024: Divi's Laboratories : Information About Proposed Capacity Addition
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Divi's Laboratories Ltd, Key Facts
- Divi's Laboratories Ltd, Key Employees
- Divi's Laboratories Ltd, Key Employee Biographies
- Divi's Laboratories Ltd, Major Products and Services
- Divi's Laboratories Ltd, History
- Divi's Laboratories Ltd, Subsidiaries
- Divi's Laboratories Ltd, Key Competitors
- Divi's Laboratories Ltd, Ratios based on current share price
- Divi's Laboratories Ltd, Annual Ratios
- Divi's Laboratories Ltd, Annual Ratios (Cont...1)
- Divi's Laboratories Ltd, Annual Ratios (Cont...2)
- Divi's Laboratories Ltd, Interim Ratios
- Divi's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Divi's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Divi's Laboratories Ltd, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Divi's Laboratories Ltd, Performance Chart (2021 - 2025)
- Divi's Laboratories Ltd, Ratio Charts
- Divi's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Divi's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
